To view this email as a web page, click here.
 
BIOSIMILAR DRUGS
 
FDA clears second Remicade biosimlar
In what is expected to produce hefty savings for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade.
Read more
 
FDA: Limit codeine and tramadol use in kids
FDA is now restricting the use of codeine and tramadol medicines in children. Find out about new warning labels and advice for prescribers and pharmacists.
Read more
 
First progressive MS drug carries high price tag
While FDA recently approved the first drug for primary progressive multiple sclerosis (PPMS), the drug's price tag is controversial.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.